Zusammenfassung
Antiallergika werden zur Behandlung der allergischen Rhinitis und Konjunktivitis, des Asthma bronchiale, allergischer Hautreaktionen (z.B. Urtikaria, Pruritus) und generalisierter allergischer Krankheiten (z.B. Insektengiftallergien, anaphylaktische Reaktionen) eingesetzt. In diesem Kapitel werden schwerpunktmäßig H1-Antihistaminika und Hyposensibilisierungsmittel besprochen. Weitere Arzneimittel für allergische Indikationen werden in den Kapiteln über Bron-chospasmolytika (), Corticosteroide (), Dermatika (), Ophthalmika () und Rhinologika (
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abramson M., Puy R., Weiner J. (1999): Immunotherapy in asthma: an updated systematic review. Allergy 54: 1022–1041.
Adelsberg B.R. (1997): Sedation and performance issues in the treatment of allergic conditions. Arch. Intern. Med. 157: 494–500.
Adkinson N.E, Eggleston P.A., Eney D., Goldstein E.O., Schuberth K.C. et al. (1997): A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 336: 324–331.
Austen K.E (1998): Diseases of immediate type hypersensitivity. In: Fauci A.S. et al. (eds.): Harrison’s principles of internal medicine. McGraw-Hill Companies Inc., New York, pp. 1860–1869.
Clavel R., Bousquet J., André C. (1998): Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53: 493–498.
Day J.H., Briscoe M., Widlitz M.D. (1998): Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J. Allergy Clin. Immunol. 101: 638–645.
Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O’Brian E, Noble W., Till S.J., Hamid Q.A., Nouri-Aria K.T. (1999): Long-term clinical efficay of grass-pollen immunotherapy. N. Engl. J. Med. 341: 468–475.
Frossard N., Lacronique J., Melac M., Benabdesselam O., Bran J.J. et al. (1997): Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 52: 205–209.
Gottlieb S. (1999): Antihistamine drug withdrawn by manufacturer. Brit. Med. J. 319: 7.
Hedlin G., Heilborn H., Lilja G., Norrlind K., Pegelow K.O. et al. (1995): Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J. Allergy Clin. Immunol. 96: 879–885.
Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. (1993): Terfenadine-ketoconazole interaction: pharmacokinetic and electrocar-diographic consequences. JAMA 269: 1513–1518.
Lüderitz-Püchel U., May S., Haustein D. (1996): Zwischenfälle nach Hyposensibili-sierung. Münch. Med. Wschr. 138: 129–132.
Meltzer E.O., Weiler J.M., Widlitz M.D. (1996): Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 97: 617–626.
Müller U., Helbling A., Berchtol E. (1992): Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allerg. Clin. Immunol. 89: 529–535.
O’Neill S.M., Forsyth A. (1988): Urticaria. Prescribers J. 28: 14–20.
Pradalier A., Basset D., Claudel A., Couturier P., Wessel R, Galvain S., André C. (1999): Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54: 819–828.
Reid M.J., Lockey R.R, Turkeltaub P.C., Platts-Mills T.A. (1993): Survey of fatalities from skin testing and immunotherapy 1985–1989. J. Allergy Clin. Immunol. 92: 6–15.
Routledge P.A., Lindquist M., Edwards I.R. (1999): Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin. Exp. Allergy 29(Suppl. 3): 240–246.
Spencer CM., Faulds D., Peters D.H. (1993): Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46: 1055–1080.
WHO Position Paper (1998): Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl. 1): 1–42.
Zenner H.P., Baumgarten C., Rasp G., Fuchs T., Kunkel G., Hauswald B. et al. (1997): Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J. Allergy Clin. Immunol. 100: 23–29.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2001). Antiallergika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56832-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-56832-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67573-0
Online ISBN: 978-3-642-56832-9
eBook Packages: Springer Book Archive